ProCE Banner Activity

Phase I/II Study of Venetoclax + Low-Dose Cytarabine in Untreated, Elderly Patients With AML: Outcomes at 1 Year

Slideset Download
Conference Coverage
After more than 1 year of follow-up, the combination of venetoclax plus low-dose cytarabine achieved a CR + CRi rate of 62% and a median OS of 11.4 months in elderly patients with AML who are unfit for chemotherapy.

Released: December 18, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology